Abstract：High dose Methotrexate is an important means in the treatment of blood tumors in children, which greatly improves the remission rate of the disease. However, its severe toxic and side effects bring great harm to children. In this paper, clinical pharmacists participated in the treatment of three children with high dose Methotrexate, and individualized pharmaceutical care was carried out according to the different conditions of the children. For children with high Methotrexate concentration or delayed elimination, timely and appropriate calcium folinate rescue strategy and symptomatic treatment can reduce the toxic reaction of Methotrexate. To ensure the efficacy of Methotrexate while minimizing the occurrence of serious adverse reactions. Finally, combined with the treatment process and literature analysis, the method of individualized treatment and pharmaceutical care for children with high dose Methotrexate by clinical pharmacists based on blood concentration monitoring was discussed.
贾晨虹 李瑞宏 秦亚彬 丁翔宇. 临床药师参与3例儿童大剂量甲氨蝶呤治疗及文献分析[J]. 中国医药导报, 2023, 20(21): 187-191.
JIA Chenhong LI Ruihong QIN Yabin DING Xiangyu. A report of three cases and literature analysis clinical pharmacist participated in high dose Methotrexate therapy in children. 中国医药导报, 2023, 20(21): 187-191.
[1] 中国临床肿瘤学会（CSCO），中国临床肿瘤学会抗白血病联盟.中国临床肿瘤学会抗淋巴瘤联盟.大剂量甲氨蝶呤亚叶酸钙解救疗法治疗恶性肿瘤专家共识[J].中国肿瘤临床，2019，46（15）：761-767.
[2] 严梓，翟宗，王易.大剂量甲氨蝶呤在儿童急性淋巴细胞白血病中的应用及研究进展[J].国际医药卫生导报，2021，27（19）：3053-3057.
[3] 国家卫生健康委办公厅.国家卫生健康委办公厅关于印发儿童血液病、恶性肿瘤相关17个病种诊疗规范（2019年版）的通知 [EB/OL]. （2019-09-05）. http：//www.nhc.gov.cn/ yzygj/ s3593/201909/5f1d3329606e4cd2-aa6e501603703 ee4.shtml.
[4] Li J，Gwilt P. The effect of malignant effusions on methotrexate disposition [J]. Cancer Chemother Pharmacol，2002，50（5）：373-382.
[5] Wright KD，Panetta JC，Onar-Thomas A，et al. Delayed meth- otrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections [J]. Cancer Chemother Pharmacol，2015，75（1）：27-35.
[6] Song Z，Hu Y，Liu S，et al. The Role of Genetic Polymorphisms in High-Dose Methotrexate Toxicity and Response in Hematological Malignancies：A Systematic Review and Meta- Analysis [J]. Front Pharmacol，2021，12：757464.
[7] 马乐，韩佳，吕冬梅.MTHFR与ABCB1基因多态性对血液系统恶性肿瘤患者大剂量甲氨蝶呤排泄延迟和肝肾毒性的影响[J].中国药业，2021，30（6）：40-43.
[8] Schulte RR，Choi L，Utreja N，et al. Effect of SLCO1B1 Polymorphisms on High-Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma [J]. Clin Transl Sci，2021，14（1）：343-353.
[9] 汤文芳.大剂量甲氨蝶呤治疗儿童急性淋巴细胞白血病的不良反应与血药浓度的关系分析[J].中国处方药，2020， 18（12）：70-71.
[10] 陈兆鑫，宋文琪.大剂量甲氨蝶呤治疗急性淋巴细胞白血病中甲酰四氢叶酸钙解救的研究进展[J].中国小儿血液与肿瘤杂志，2021，26（1）：56-59.
[11] Alsdorf WH，Karagiannis P，Langebrake C，et al. Standardized Supportive Care Documentation Improves Safety of High-Dose Methotrexate Treatment [J]. Oncologist，2021， 26（2）：e327-e332.
[12] 李思婵，汪洋，陈渝军，等.大剂量甲氨蝶呤消除相末端药时曲线下面积的相关因素分析[J].中国医院药学杂志，2016，36（22）：1988-1992.
[13] Schmidt D，Kristensen K，Schroeder H. Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia：A Danish population-based study [J]. Pediatr Blood Cancer，2019，66（6）：e27637.
[14] Gao X，Qian XW，Zhu XH，et al. Population Pharmacokinetics of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia [J]. Front Pharmacol，2021，12：701452.
[15] Niinimki R，Aarnivala H，Banerjee J，et al. Reduced dose fol- inic acid rescue after rapid high-dose methotrexate clearance is not associated with increased toxicity in a pediatric cohort [J]. Support Care Cancer，2022，30（1）：127-133.
[16] Chen AR，Wang YM，Lin M，et al. High-Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia：Predictors of Delayed Clearance and the Effect of Increased Hydration Rate on Methotrexate Clearance [J]. Cureus，2020，12（6）：e8674.
[17] Zhan M，Chen Z，Ding C，et al. Risk prediction for delayed clearance of high-dose methotrexate in pediatric hematological malignancies by machine learning [J]. Int J Hematol，2021，114（4）：483-493.
[18] Nakano T，Kobayashi R，Matsushima S，et al. Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma [J]. Int J Hematol，2021，113（5）：744-750.
[19] 孙建明，周光庭.大剂量甲氨蝶呤治疗儿童急性淋巴细胞白血病消除延迟的影响因素及不良反应[J].临床合理用药杂志，2022，15（7）：41-46.
[20] 吴雪梅，林世光，郑译.大剂量甲氨蝶呤治疗儿童急性淋巴细胞白血病的血药浓度变化及影响因素研究[J].临床合理用药杂志，2017，10（36）：59-60.
[21] Traivaree C，Likasitthananon N，Monsereenusorn C，et al. The effect of intravenous hydration strategy on plasma methotrexate clearance during intravenous high-dose met- hotrexate administration in pediatric oncology patients [J]. Cancer Manag Res，2018，10：4471-4478.
[22] Ramsey LB，Balis FM，O’Brien MM，et al. Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance [J]. Oncologist，2018，23（1）：52-61.
[23] Mateos MK，Marshall GM，Barbaro PM，et al. Methotrexate-related central neurotoxicity：clinical characteristics，risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia [J]. Haematologica，2022，107（3）：635-643.
[24] Cohen IJ. Neurotoxicity after high-dose methotrexate（MTX） is adequately explained by insufficient folinic acid rescue [J]. Cancer Chemother Pharmacol，2017，79（6）：1057-1065.
[25] Valer JB，Curra M，Gabriel AF，et al. Oral mucositis in childhood cancer patients receiving high-dose methotrexate：Prevalence，relationship with other toxicities and methotrexate elimination [J]. Int J Paediatr Dent，2021，31（2）：238- 246.
京公网安备 11010502046598号